Novogen (ASX: NRT) ​- Picking up where Genentech left off

Stuart Roberts

Today NDF Research initiates coverage on Novogen, a Sydney-based cancer drug developer whose lead compound, soon to enter Phase 2, is GDC-0084, for the treatment of glioblastoma. Show More

life sciences ASX:NRT NDF Research

Daily AGM Note 12 November 2015 - a first strike at Zeus Resources

Avatar fallback

A big day for All the Majors AGMs and while the ASX 100 AGMs appear to be fine, some smaller AGM results are interesting - Comet Resources Limited, Rubicor Group, Regis Resources, Novogen and Emerchants Limited. Emerchants vote of interest is on the ASX Listing Rule 7.1A resolution for an... Show More